Navigation Links
Nanowires can detect molecular signs of cancer, scientists find

Use of minuscule devices to spot cancer markers could lead to ultra-powerful new diagnostics

Harvard University researchers have found that molecular markers indicating the presence of cancer in the body are readily detected in blood scanned by special arrays of silicon nanowires -- even when these cancer markers constitute only one hundred-billionth of the protein present in a drop of blood. In addition to this exceptional accuracy and sensitivity, the minuscule devices also promise to pinpoint the exact type of cancer present with a speed not currently available to clinicians.

A paper describing the work will appear in October in the journal Nature Biotechnology and is now posted on the journal's web site.

"This is one of the first applications of nanotechnology to healthcare and offers a clinical technique that is significantly better than what exists today," says author Charles M. Lieber, Mark Hyman Jr. Professor of Chemistry in Harvard's Faculty of Arts and Sciences. "A nanowire array can test a mere pinprick of blood in just minutes, providing a nearly instantaneous scan for many different cancer markers. It's a device that could open up substantial new possibilities in the diagnosis of cancer and other complex diseases."

Lieber and his colleagues linked slender nanowires conducting a small current with antibody receptors for certain cancer markers -- such as prostate specific antigen (PSA), PSA-a1-antichymotrypsin, carcinoembryonic antigen and mucin-1. When these telltale proteins come into contact with a receptor, it sparks a momentary change in conductance that gives a clear indication of the marker's presence. The detectors differentiate among various cancer markers both through the specific receptors used to snag them and because each binds its receptor for a characteristic length of time before dislodging.

"Our results show that these devices are able to distinguish among molecules with near-perfect selectivity," L ieber says, adding that the risk of false readings is minimized by the incorporation of various control nanowires.

The scientists also fitted some nanowires in the arrays with nucleic acid receptors for telomerase, an enzyme inactive in most of the body's somatic cells but active in at least 80 percent of known human cancers. In testing of extracts from as few as 10 tumor cells, these receptors allowed real-time monitoring of telomerase binding and activity.

Lieber says nanowire arrays could easily be scaled up to detect many different cancer markers -- more of which are being found all the time, thanks to the current boom in proteomics. Widespread use of these cancer markers in healthcare will ultimately depend upon the development of techniques that allow rapid detection of many markers with high selectivity and sensitivity.

"Genomics and proteomics research has elucidated many new biomarkers that have the potential to greatly improve disease diagnosis," the scientists write. "The availability of multiple biomarkers is believed to be especially important in the diagnosis of complex diseases like cancer, for which disease heterogeneity makes tests of single markers inadequate. Patterns of multiple cancer markers might, however, provide the information necessary for robust diagnosis of disease ?[and] detection of markers associated with different stages of disease pathogenesis could further facilitate early detection."

While initial rounds of cancer testing today identify only whether or not cancer is present, nanowire arrays have the potential to immediately fill in details on exactly what type of cancer is present. Nanowires could also track patients' health as treatment progresses. Because the arrays detect molecules suspended in fluids, drops of blood could be tested directly, in a physician's office, without any need for biochemical manipulation.

Lieber's co-authors are Gengfeng Zheng, Fernando Patolsky, Yi Cui and Wayne U. Wang, all of Harvard's Department of Chemistry and Chemical Biology, Biophysics Program and Division of Engineering and Applied Sciences. The work was supported by the Defense Advanced Research Projects Agency and the National Cancer Institute.


'"/>

Source:Harvard University


Related biology news :

1. Novel technology detects human DNA mutations
2. Researchers find how protein allows insects to detect and respond to pheromones
3. Scientists detect probable genetic cause of some Parkinsons disease cases
4. Development of portable infectious disease detector
5. Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells
6. Yale researchers identify molecule for detecting parasitic infection in humans
7. Robot-based system developed at Carnegie Mellon detects life in Chiles Atacama desert
8. Products containing specific probes for detecting alternative splice forms protected
9. Nanoparticles offer new hope for detection and treatment
10. Test for early detection of prostate cancer shows promise
11. Confocal imaging promises early detection of skin cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/21/2016)... , June 21, 2016 NuData Security announced ... new role of principal product architect and that ... director of customer development. Both will report directly ... officer. The moves reflect NuData,s strategic growth in ... to high customer demand and customer focus values. ...
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
(Date:6/2/2016)... -- Perimeter Surveillance & Detection Systems, Biometrics ... Support & Other Service  The latest report ... analysis of the global Border Security market . ... $17.98 billion in 2016. Now: In November ... software and hardware technologies for advanced video surveillance. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
Breaking Biology Technology: